Granted Patent
B2
US 12,358,984 · App. 16/966,968 · Granted Jul 15, 2025
Methods for treating cancer with anti-PD-1 antibodies
Assignee:
Merck Sharp & Dohme LLC
C07K16/2818A61K39/39541A61K47/22A61K47/26A61P35/00A61K2039/505A61K2039/545C07K2317/51C07K2317/515C07K2317/56
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to methods for treating cancer in a patient comprising administering a PD-1 antagonist, e.g., an anti-PD-1 antibody or antigen binding fragment thereof (e.g. pembrolizumab), in specific amounts to the patient about every six weeks. In some embodiments, the amount of anti-PD-1 antibody or antigen binding fragment thereof is about 400 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.
Claims (28)
1. A method of treating cancer in a human patient comprising administering 400 mg of pembrolizumab to the patient every approximately six weeks.
2. The method of claim 1 , wherein the cancer is selected from the group consisting of: melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastric cancer, multiple myeloma, hepatocellular cancer, non-Hodgkin lymphoma, renal cancer, Hodgkin lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, endometrial cancer, squamous cell carcinoma, Merkel cell carcinoma and salivary cancer.
3. The method of claim 1 , wherein the patient has a tumor with a high mutational burden.
4. The method of claim 1 , wherein the patient has a microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumor.
5. The method of claim 1 , wherein the cancer is melanoma.
6. The method of claim 1 , wherein the cancer is non-small cell lung cancer.
7. The method of claim 1 , wherein the cancer is head and neck cancer.
8. The method of claim 2 , wherein the Hodgkin lymphoma is classical Hodgkin lymphoma cancer.
9. The method of claim 1 , wherein the cancer is urothelial cancer.
10. The method of claim 1 , wherein the cancer is colorectal cancer.
11. The method of claim 1 , wherein the cancer is gastric cancer.
12. The method of claim 1 , wherein the cancer is esophageal cancer.
13. The method of claim 1 , wherein the cancer is cervical cancer.
14. The method of claim 1 , wherein the cancer is hepatocellular cancer.
15. The method of claim 1 , wherein the cancer is Merkel cell carcinoma.
16. The method of claim 1 , wherein the cancer is renal cancer.
17. The method of claim 1 , wherein the cancer is endometrial cancer.
18. The method of claim 1 , wherein the cancer is breast cancer.
19. The method of claim 5 , wherein the cancer is unresectable or metastatic melanoma.
20. The method of claim 7 , wherein the cancer is recurrent or metastatic head and neck squamous cell cancer (HNSCC).
21. The method of claim 1 , wherein the cancer is (1) refractory classical Hodgkin lymphoma (cHL), or (2) cHL and the patient has relapsed after 3 or more lines of therapy for cHL.
22. The method of claim 9 , wherein the cancer is locally advanced or metastatic urothelial carcinoma.
23. The method of claim 1 , wherein the cancer is locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
24. The method of claim 1 , wherein the cancer is resected high-risk stage III melanoma.
25. The method of claim 1 , wherein the cancer is hepatocellular carcinoma (HCC).
26. The method of claim 1 , wherein the cancer is renal cell carcinoma (RCC).
27. The method of claim 1 , wherein the cancer is recurrent, locally advanced or metastatic Merkel cell carcinoma (MCC).
28. The method of claim 1 , wherein the cancer is squamous cell carcinoma.
Assignments (2)
MERGER
Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 3, 2020
From: LALA, MALLIKA; JAIN, LOKESH; LI, MENGYAO
To: MERCK SHARP & DOHME CORP.
Reel/Frame 053382/0133 →
Continuity (3)
Provisional Application
62732828
· Sep 18, 2018
Provisional Application
62630038
· Feb 13, 2018
References Cited (143)
US 9220776B2
· Sharma
· 2015
[cited by third party]
US 20170313775A1
· Diaz
· 2017
[cited by third party]
JP 2017530950A
· 2017
[cited by applicant]
MX 2019002946A
· 2019
[cited by applicant]
MX 2019008207A
· 2019
[cited by applicant]
WO 2008156712A1
· 2008
[cited by applicant]
WO 2012135408A1
· 2012
[cited by applicant]
WO 2014100079A1
· 2014
[cited by applicant]
WO 2015095423A2
· 2015
[cited by applicant]
WO 2016032927A1
· 2016
[cited by applicant]
WO 2016137850A1
· 2016
[cited by applicant]
WO 2016176504A1
· 2016
[cited by third party]
WO 2016196389A1
· 2016
[cited by applicant]
WO 2017106656A1
· 2017
[cited by applicant]
WO 2017127811A1
· 2017
[cited by third party]
WO 2017151502A1
· 2017
[cited by applicant]
WO WO2017165125A1
· 2017
[cited by examiner]
WO 2017205216A1
· 2017
[cited by third party]
WO 2017197263A1
· 2017
[cited by applicant]
WO 2017210624A1
· 2017
[cited by third party]
WO 2018053106A1
· 2018
[cited by applicant]
WO 2018129559A1
· 2018
[cited by applicant]
Ahmadzadeh et al., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 2009, 1537-1544, 114.
[cited by applicant]
Baert et al., Influence of Immunogenicity on the long term efficacy of Infliximab in Crohns disease, New England Journal Med., 2003, pp. 601-608, 348.
[cited by applicant]
Beniaminovitz et al., Prevention of rejection in cardiac transplantation by blockade of the interleukin 2 receptor with a monoclonal antibody, New England Journal of Medicine, 2000, pp. 613-619, 342.
[cited by applicant]
Brahmer et al., Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer, the New England Journal of Medicine, 2012, pp. 2455-2465, vol. 366, No. 26.
[cited by applicant]
Chen et al., PD-L1 Expression is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies, Clinical Cancer Research, 2013, pp. 3462-3473, vol. 19.
[cited by applicant]
Dang, T.O. et al., Pembrolizumab for the treatment of PD-LI positive advanced or metastatic non-small cell lung cancer, Expert Review of Anticancer Therapy, 2015, 1-23, 11:43.
[cited by applicant]
Dong et al., Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion, Nature Medicine, 2002, pp. 793-800, vol. 8(8).
[cited by applicant]
Freshwater, T. et al., Evaluation of dosing strategy for pembrolizumab for oncology indications, Journal for ImmunoTherapy of Cancer, 2017, 1-9, 5:43.
[cited by applicant]
Gadiot et al., Overall Survival and PD-L1 Expression in Metastasized Malignant Melanoma, Cancer, 2011, 2192-2201, 117.
[cited by applicant]
Gao et al., Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma, Clinical Cancer Research, 2009, 971-979, 15.
[cited by applicant]
Garon et al., Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer, the New England Journal of Medicine, 2015, pp. 2018-2028, vol. 372, No. 21.
[cited by applicant]
Ghebeh et al., FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy, BMC Cancer, 2008, 57-68, 8.
[cited by applicant]
Ghebeh et al., The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors, Neoplasia, 2006, 190-…
[cited by applicant]
Ghosh et al., Natalizumab for active Crohns disease, New England J. Med., 2003, pp. 24-32, 348.
[cited by applicant]
Hamanishi et al., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer, Proceedings of the National Academy of Sciences USA, 2007, 3360-3365, 104.
[cited by applicant]
Hamid et al., Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma, New Eng. J. Med., 2013, 134-144, 369(2).
[cited by applicant]
Hino et al., Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer, 2010, 1757-1766, 116(7).
[cited by applicant]
Inman et al., PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression, Cancer, 2007, 1499-1505, 109.
[cited by applicant]
Lipsky et al., Infliximab and methotrexate in the treatment of rheumatoid arthritis, New England Journal of Medicine, 2000, pp. 1594-1602, 343.
[cited by applicant]
Milgrom et al., Treatment of allergic asthma with monoclonal anti IgE antibody, New England Journal Med., 1999, pp. 1966-1973, 341.
[cited by applicant]
Nakanishi et al., Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers, Cancer Immunol. Immunother., 2007, 1173-1182, 56.
[cited by applicant]
Nomi et al., Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer, Clinical Cancer Research, 2007, pp. 2151-2157, vol. 13.
[cited by applicant]
Ohigashi et al., Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer, Clin. Cancer Research, 2005, 2947-2953, 11.
[cited by applicant]
Robert et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, the Lancet, 2014, pp. 1109-1117, vol. 384.
[cited by applicant]
Robert et al., Nivolumab in Previously Untreated Melanoma without BRAF Mutation, the New England Journal of Medicine, 2015, pp. 320-330, vol. 372, No. 4.
[cited by applicant]
Robert et al., Pembrolizumab versus Ipilimumab in Advanced Melanoma, the New England Journal of Medicine, Jun. 25, 2015, pp. 2521-2532, 372.
[cited by applicant]
Sharpe et al., The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection, Nature Immunology, 2007, 239-245, 8.
[cited by applicant]
Shimauchi et al., Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma, Int. J. Cancer, 2007, 2585-2590, 121.
[cited by applicant]
Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, New England J. Med., 2001, pp. 783-792, 344.
[cited by applicant]
Taube, et al., Colocalization of inflammatory response with B7-H1 expression in humna melanocytic lesions supports an adaptive resistance mechanism of ummune escape, Sci Transl Med, 2012, pp. 127ra37, vol. 4.
[cited by applicant]
Thompson et al., Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target, Proc. Nat'l Acad. Sci. USA, 2004, 17174-17179, 101(49).
[cited by applicant]
Thompson et al., PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma, Clinical Cancer Research, 2007, pp. 1757-1761, vol. 15.
[cited by applicant]
Thompson et al., Significance of B7-H1 Overexpression in Kidney Cancer, Cancer, 2006, 206-211, 5.
[cited by applicant]
Thompson et al., Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-Term Follow-up, Cancer Res., 2006, pp. 3381-3385, vol. 66.
[cited by applicant]
Topalian et al., Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, New Eng. J. Med., 2012, 2443-2454, 366(26).
[cited by applicant]
Topalian et al., Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab, Clinical Journal of Oncology, 2014, pp. 1020-1030, vol. 32, No. 10.
[cited by applicant]
Weber, Wolfgang A., Assessing Tumor Response to Therapy, Journal of Nuclear Medicine, 2009, 1S-10S, 50.
[cited by applicant]
WHO Drug Information, vol. 27, No. 2, pp. 161-162 (2013).
[cited by applicant]
Wolchok et al., Nivolumab plus Ipilimumab in Advanced Melanoma, the New England Journal of Medicine, 2013, pp. 122-133, vol. 369(2).
[cited by applicant]
Yang et al., PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro, Invest Ophthalmol Vis Sci, 2008, 2518-2525, 49(6).
[cited by applicant]
Zhao et al., A Model-Based Exposure-Response (E-R) Assessment of a Nivolumab (NIVO) 4-Weekly (Q4W), AACR, 2017.
[cited by applicant]
Zhao, X. et al., Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types, AACR, 2017, 1-4, N/A.
[cited by applicant]
Castellino, Alexander M., Pembrolizumab Flat Dosing Wastes Nearly $1 Billion Annually, Medscape Medical NewsConference NewsAmerican Society of Clinical Oncology (ASCO) 2017 Annual Meeting, 2017, 1-3, N/A.
[cited by applicant]
Elassaiss-Schaap, J. et al., Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the Keynote-001 Trial : Modeling of the PK/PD of Pembro in Keynote-001,…
[cited by applicant]
Goldstein, Daniel A. et al., A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-LI positive non-small cell lung cancer, Journal of Clinical Oncology, 2017, Abstract 9…
[cited by applicant]
Lala, Mallika et al., A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation, European Journal of Cancer, 2020, 68-75, 131.
[cited by applicant]
Walker, Scott et al., Dosing and Timing of Immuno-Oncology Drugs, CADTH Technology Review: Optimal Use 360 Report, 2019, 1-50, 25.
[cited by applicant]
Ott, Patrick A. et al., Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the Keynote-028 Study, J Clin Oncol, 2017, 2535-2541, 35(22).
[cited by applicant]
Pembrolizumab (Rx). Medscape. Sep. 18, 2017. found on Aug. 30, 2022, URL: https://web.archive.org/web/20170918010806/http://reference.medscape.com/drug/keytruda-pembrolizumab-999962 (5 pages).
[cited by applicant]
Kwok, Gerry et al., Pembrolizumab (Keytruda), Human Vaccines & Immunotherapeutics, 2016, 2777-2789, 12:11.
[cited by applicant]
Cooper, L J et al., Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains, J Immunol, 150(6), 223…
[cited by applicant]
Liang, Wei-Ching et al., Dramatic activation of an antibody by a single amino acid change in framework, Scientific Reports, 11:22365, 1-9, 2021.
[cited by applicant]
McDermott, et al., PD-1 as a potential target in cancer therapy, Cancer Medicine, pp. 662-673, 2013, WO.
[cited by applicant]
Montano, R.F. et al., Influence of the isotype of the light chain on the properties of IgG, the Journal of Immunology, 168, 224-231, 2002.
[cited by applicant]
A. Baumann, Early Development of Therapeutic Biologics—Pharmacokinetics, Current Drug Metabolism, 7, 15-21, 2006.
[cited by applicant]
Agoram, Balaji M. et al., The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics, Drug Discovery Today, 12(23/24), 1018-1024, 2007.
[cited by applicant]
Ahamadi, M. et al., Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumor, CPT Pharmacometrics Syst. Pharmacol., 6, 49-57, 2017.
[cited by applicant]
Azanza, J-R et al., Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens?, J Oncol Pharm Practice, 0(0), 1-7, 2014.
[cited by applicant]
Bai, Shuang et al., A Guide to Rational Dosing of Monoclonal Antibodies, Clin Pharmacokinet, 51(2), 119-135, 2012.
[cited by applicant]
Baselga, J. et al., Phase I Studies of Anti-Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin, J Clin Oncol, 18, 904-914, 2000.
[cited by applicant]
Baxter, Laurence T. et al., Biodistribution of Monoclonal Antibodies: Scale-up from Mouse to Human Using a Physiologically Based Pharmacokinetic Model, Cancer Research, 55, 4611-4522, 1995.
[cited by applicant]
Bruno, Rene et al., Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer, Cancer Chemother Pharmacol, 56, 361-369, 2005.
[cited by applicant]
CADTH, Dosing and Timing of Immuno-Oncology Drugs, CADTH, N/A, 3 pages, 2020.
[cited by applicant]
Cao, Yanguang et al., Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies, J Pharmacokinet Pharmacodyn, 40, 597-607, 2013.
[cited by applicant]
Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review(s), Center for Drug Evaluation and Research, N/A, 1-43, 2014.
[cited by applicant]
Chatterjee, M. et al., Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer, Annals of Oncology, 27, 1291-1298, 2015.
[cited by applicant]
Chatterjee, MS et al., Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma, CPT Pharmacometrics Syst. Pharmacol., 6, 29-39, 2017.
[cited by applicant]
De Greef, R. et al., Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma, CPT Pharmacometrics Syst. Pharmacol., 6, 5-7, 2017.
[cited by applicant]
Dirks, Nathanael L. et al., Population Pharmacokinetics of Therapeutic Monoclonal Antibodies, Clin Pharmacokinet, 49(10), 633-659, 2010.
[cited by applicant]
European Medicines Agency, Guideline on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins, European Medicines Agency, CHMP/EWP/89249/2004, 11 pages, 2007.
[cited by applicant]
FDA, Review Memo—Keytruda, FDA, N/A, 19 pages, 2020.
[cited by applicant]
Food and Drug Administration, FDA approves new dosing regimen for pembrolizumab, Food and Drug Administration, N/A, 2 pages, 2020.
[cited by applicant]
Grimwood, Sarah et al., Target site occupancy: Emerging generalizations from clinical and preclinical studies, Pharmacology & Therapeutics, 122, 281-301, 2009.
[cited by applicant]
Hamid, Omid et al., Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPIR) and IPI-naive (IPI-N) melanoma (MEL), Journal of Clinical Oncology, 32(Suppl15), Abstr…
[cited by applicant]
Hendrikx, Jeroen J.M.A. et al., Fixed Dosing of Monoclonal Antibodies in Oncology, the Oncologist, 22, 1212-1221, 2017.
[cited by applicant]
Herbst, Roy S et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (Keynote-010): a randomised controlled trial, Lancet, 387, 1540-1550, 2016.
[cited by applicant]
Jiunn H. Lin, Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies, Current Drug Metabolism, 10, 661-691, 2009.
[cited by applicant]
Jones, Hannah M. et al., A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data, CPT Pharmacometrics Syst. Pharmacol., 8, 738-747, 2019.
[cited by applicant]
Keizer, Ron J. et al., Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies, Clin Pharmacokinet, 49(8), 493-507, 2010.
[cited by applicant]
Kontermann, Roland, Strategies to Extend Plasma Half-Lives of Recombinant Antibodies, Biodrugs, 23(2), 93-109, 2009.
[cited by applicant]
Koren, E. et al., Immune Responses to Therapeutic Proteins in Humans—Clinical Significance, Assessment and Prediction, Current Pharmaceutical Biotechnology, 3, 349-360, 2002.
[cited by applicant]
Lee, Jean W et al., Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics, Bioanalysis, 4(20), 2513-2523, 2012.
[cited by applicant]
Li, Hongshan et al., Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response, J Pharmacokinet Pharmacodyn, 44, 403-414, 2017.
[cited by applicant]
Li, Tommy R. et al., Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology, Clinical Pharmacology & Therapeutics, 110(1), 200-209, 2021.
[cited by applicant]
Lindauer, A et al., Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab, CPT Pharmacometrics Syst. Pharmacol., 6, 11-20…
[cited by applicant]
Lobo, Evelyn D. et al., Antibody Pharmacokinetics and Pharmacodynamics, J Pharm Sci, 93(11), 2645-2668, 2004.
[cited by applicant]
Lynch, Carmel M. et al., Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies, mAbs, 1:1, 2-11, 2009.
[cited by applicant]
Marianne J. H. Van Vugt, et al., Immunogenicity of pembrolizumab in patients with advanced tumors, Journal for Immuno Therapy of Cancer, 7:212, 1-8, 2019.
[cited by applicant]
Mould, D. R. et al., Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development, CPT: Pharmacometrics & Systems Pharmacology, 1:e6, 1-14, 2012.
[cited by applicant]
Mould, Diane R et al., The pharmacokinetics and pharmacodynamics of monoclonal antibodies—mechanistic modeling applied to drug development, Current Opinion in Drug Discovery & Development, 10(1), 84-96, 2007.
[cited by applicant]
Mould, DR et al., Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods, CPT: Pharmacometrics & Systems Pharmacology, 2(e38), 1-14, …
[cited by applicant]
Newsome, Barrett W. et al., The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?, Br J Clin Pharmacol, 66:1, 6-19, 2008.
[cited by applicant]
Peletier, Lambertus A. et al., Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification, J Pharmacokinet Pharmacodyn, 39, 429-451, 2012.
[cited by applicant]
Putnam, Wendy S. et al., Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies, Trends in Biotechnology, 28(10), 509-516, 2010.
[cited by applicant]
Ribas, Antoni et al., Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma, JAMA, 315(15), 1600-1609, 2016.
[cited by applicant]
Ribas, Antoni et al., Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (Keynote-002): a randomised, controlled, phase 2 trial, Lancet Oncol, 16, 908-918, 2015.
[cited by applicant]
Rippe, B. et al., Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations, Acta Physiol Scand, 131, 411-428, 1987.
[cited by applicant]
Sachs, Jeffrey R. et al., Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example, Clin Cancer Res, 22(6), 1318-1324, 2016.
[cited by applicant]
Upton, RN et al., Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods, CPT Pharmacometrics Syst. Pharmacol., 3(e88), 1-16, 2014.
[cited by applicant]
US Dept of Health & Human Services Food & Drug Admin, Guidance for Industry-Exposure-Response Relationships—Study Design, Data Analysis, and Regulatory, US Dept of Health & Human Services Food & Drug Admin, N/A, 1-28, 2…
[cited by applicant]
Wang, Diane D. et al., Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials, Journal of Clinical Pharmacology, 49, 1012-1024, 2009.
[cited by applicant]
Wang, W. et al., Monoclonal Antibody Pharmacokinetics and Pharmacodynamics, Nature, 84(5), 548-558, 2008.
[cited by applicant]
Vugmeyster, Yulia et al., Biodistribution of [125I]-Labeled Therapeutic Proteins: Application in Protein Drug Development Beyond Oncology, J Pharm Sci, 99(2), 1028-1045, 2010.
[cited by applicant]
Zhu, Hui et al., Tumor Pretargeting for Radioimmunodetection and Radioimmunotherapy, J Nucl Med, 39, 65-76, 1998.
[cited by applicant]
Dang, et al., “Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer”, Expert Rev Anticancer Ther., vol. 16(1), pp. 13-20, 2016.
[cited by applicant]
Ernstoff, Marc S., “The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?”, British Journal of Clinical Pharmacology, vol. 6:1, pp. 6-19, May 22, …
[cited by applicant]
Food and Drug Administration, Guidance for Industry Population Pharmacokinetics, CP 1, N/A, 35 pages, 1999.
[cited by applicant]
Glassman, Patrick M., et al., “Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens”, MABS, vol. 9:2, pp. 297-306, 2017.
[cited by applicant]
Hansel, Trevor T., et al., “The safety and side effects of monoclonal antibodies”, Nature Reviews Drug Discovery, vol. 9, pp. 325-338, Apr. 2010.
[cited by applicant]
Jain, Rajul K. et al., “Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse”, American Association for Cancer Research., vol. 16(4), pp. 1289-1297, 2010.
[cited by applicant]
Mathijssen, Ron H. J., et al., “Determining the optimal dose in the development of anticancer agents”, Nature Reviews Clinical Oncology, vol. 11, pp. 272-281, May 2014.
[cited by applicant]
Nghiem, Paul T., et al., “PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma”, N Engl J Med, 374;26, 2542-2552, 2016.
[cited by applicant]
Ryman, Josiah T., et al., “Pharmacokinetics of Monoclonal Antibodies”, CPT Pharmacometrics Syst. Pharmacol., vol. 6, pp. 576-588, 2017.
[cited by applicant]
Tosi, Diego, et al., “Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies”, American Society of Clinical Oncology, vol. 33, pp. 2158-2165, 2015.
[cited by applicant]
Truong, Phu et al., Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab, Cureus, 8(6): e631, 1-3, 2016.
[cited by applicant]
Wong, et al, “Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?”, thelancet. com, vol. 16, pp. 1287-1288, Oct. 2015.
[cited by applicant]
Zinzani, Pier Luigi et al., Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma, Blood, 130(3), 267-270, 2017.
[cited by applicant]
Bates, Adam et al., David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments, Antibodies, 8(2), 1-31, 2019.
[cited by applicant]
Freshwater et al., Evaluation of dosing strategy for pembrolizumab for oncology indications, Journal for ImmunoTherapy of Cancer, vol. 5, Article No. 43 (2017).
[cited by third party]